BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. [electronic resource]
Producer: 20130130Description: 791-7 p. digitalISSN:- 2159-8290
- Aged
- Cell Line, Tumor
- Genome, Human
- Humans
- MAP Kinase Kinase Kinases -- antagonists & inhibitors
- MAP Kinase Signaling System -- drug effects
- Male
- Melanoma -- drug therapy
- Mutation
- Protein Kinase Inhibitors -- therapeutic use
- Proto-Oncogene Proteins B-raf -- genetics
- Pyridones -- therapeutic use
- Pyrimidinones -- therapeutic use
No physical items for this record
Publication Type: Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.